About the Company
We do not have any company description for Black Diamond Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
NasdaqGS:BDTX 1 Year Share Price vs Fair Value Explore Black Diamond Therapeutics's Fair Values from the Community ...
Black Diamond Therapeutics And 2 Promising Penny Stocks For Savvy Investors
As the major U.S. stock indices hover near record highs following two consecutive weeks of gains, investors are closely monitoring economic indicators and corporate earnings for signs of market ...
Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership oppo ...
How Many Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Do ...
We can report that insiders do own shares in Black Diamond Therapeutics, Inc.. It has a market capitalization of just US$276m, and insiders have US$9.2m worth of shares, in their own names.
Servier and Black Diamond Therapeutics Announce Global Licensing ...
SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics ...
Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug ...
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is among the best get rich quick stocks to buy now. Analysts at Raymond James have reinitiated coverage on Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) ...
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics ...
--Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the formation of Launchpad Therapeutics ...
Black Diamond Therapeutics to Host Webcast Presentation of Initial ...
CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of ...
Algert Global LLC Takes Position in Black Diamond Therapeutics, Inc ...
Black Diamond Therapeutics, Inc. has a 12 month low of $1.62 and a 12 month high of $7.66. The firm has a market capitalization of $188.18 million, a P/E ratio of -2.22 and a beta of 2.47.
Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports ...
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of ...
Black Diamond Therapeutics takes lab, office space at Alexandria Center ...
Black Diamond Therapeutics Inc., a precision oncology medicine company, has inked a deal for more than 18,000 square feet at the Alexandria Center for Life Science at 430 E. 29th St. in Kips Bay.
Servier and Black Diamond Therapeutics Announce Global Licensing ...
Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.
Similar Companies
Loading the latest forecasts...